Related Experiment Video
Updated: Aug 5, 2026
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Expert Consensus to Explore the Definition and Characterization of Methamphetamine-Associated Pulmonary Arterial
Roham Zamanian1, Peter J Leary2, Therese Sargent3
1Pulmonary and Critical Care, Stanford University School of Medicine, Stanford, CA.
Background:
Methamphetamine use can result in methamphetamine-associated pulmonary arterial hypertension (Meth-APAH). Compared with idiopathic pulmonary arterial hypertension (PAH), Meth-APAH may have a worse clinical course.
Research Question:
How can methamphetamine use status be classified and what are the associated treatment considerations for patients with Meth-APAH?
Study Design And Methods:
US-based experts (N = 12) who manage patients with Meth-APAH were recruited to a double-blinded, modified Delphi panel (2 survey rounds and a virtual consensus meeting). During the survey rounds, panelists answered a range of questions with free-text responses or rating statements. For rating questions, consensus was defined as ≥ 80% of panelists rating their agreement (from 7 to 9) or disagreement (from 1 to 3) using a 9-point Likert scale.
Results:
The panel was unable to reach consensus on the definition of Meth-APAH. Although there was general agreement that Meth-APAH is a group 1 PAH diagnosis in a patient with a history of methamphetamine use, a number of panelists thought that additional details were needed (eg, duration, cumulative exposure) and these details could not be agreed on. The panel agreed that Meth-APAH is heterogeneous in disease course and physicians should explore the potential of methamphetamine use in all new and existing cases of PAH regardless of the regional prevalence of methamphetamine use. The panel achieved consensus that patients with Meth-APAH should be treated for both PAH and drug addiction. There are no Meth-APAH-specific barriers to double combination therapy (ie, endothelin receptor antagonists, phosphodiesterase 5 inhibitors), but a range of patient and disease factors may influence the choice and route of delivery for other therapies.
Interpretation:
The characterization of Meth-APAH may help facilitate the identification, treatment, and management of patients with Meth-APAH to improve clinical outcomes.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...